Clinical Report: Molecular Pathology Insights into Non-Malignant Hematological Disorders
Overview
This review discusses the significant role of molecular pathology in diagnosing and managing non-malignant hematological disorders, particularly focusing on haemoglobinopathies such as sickle cell disease and thalassaemia. It highlights the prevalence and morbidity associated with these conditions, emphasizing the need for advanced diagnostic and therapeutic approaches.
Background
Molecular pathology has revolutionized the understanding and management of hematological diseases, which are a leading genetic cause of global mortality and morbidity. Among these, disorders of red blood cells, particularly haemoglobinopathies, are prevalent and have significant impacts on health. Understanding the genetic underpinnings of these conditions is crucial for improving patient outcomes and developing targeted therapies.
Data Highlights
Condition
Deaths (2017)
Global Prevalence
Years Lived with Disability (YLD)
Thalassaemias
7,200
N/A
N/A
Sickle Cell Disorders
38,400
3 million
N/A
G6PD Deficiency
16,700
N/A
N/A
Other Haemoglobinopathies
42,200
N/A
N/A
Key Findings
Haemoglobinopathies and haemolytic anaemias affect approximately 2 billion people globally.
In 2017, there were 104,600 deaths attributed to haemoglobinopathies and haemolytic anaemias.
The Global Burden of Disease study reported 6,572 million YLDs linked to haemoglobinopathies and haemolytic anaemias.
Approximately 7% of the world’s population are carriers of a potentially pathological haemoglobin gene.
There are significant variations in morbidity and mortality data for non-malignant haematological diseases.
Clinical Implications
The findings underscore the importance of genetic testing and molecular diagnostics in managing non-malignant hematological disorders. Clinicians should be aware of the high prevalence and associated morbidity of haemoglobinopathies to improve patient care and management strategies.
Conclusion
Molecular pathology provides critical insights into non-malignant hematological disorders, highlighting the need for ongoing research and advancements in diagnostic and therapeutic approaches.
